Intracellular signal transduction pathway proteins as targets for cancer therapy

Alex A Adjei1, Manuel Hidalgo

  • 1Division of Medical Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA. adjei.alex@mayo.edu

Insights

Cancer cells hijack normal cell signaling pathways involving growth factors and kinases for tumor growth. Targeting these intracellular signaling networks offers a promising strategy for novel cancer therapies currently in clinical trials.

Area of Science:

  • Cellular Biology
  • Molecular Oncology
  • Pharmacology

Background:

  • Cellular processes like proliferation and apoptosis are regulated by circulating factors.
  • Intracellular signaling cascades, particularly kinase signaling, transmit these signals.
  • Cancer cells exploit these pathways for growth and metastasis, making them therapeutic targets.

Purpose of the Study:

  • To review intracellular signaling networks critical in cancer.
  • To focus on pathways with inhibitors in clinical development.
  • To explore the therapeutic potential of targeting abnormal cell signaling in malignancies.

Main Methods:

  • Literature search of MEDLINE (1966-2005) using keywords: signal transduction, intracellular signaling, kinases, proliferation, growth factors, cancer therapy.
  • Inclusion of original research and review articles on intracellular signaling in oncogenesis and therapeutic interventions.
  • Supplemented by manual searches of major cancer research conference proceedings.

Main Results:

  • Intracellular signaling pathways are frequently dysregulated in cancer.
  • Several key signaling pathways are targeted by novel therapeutic agents.
  • Inhibitory agents targeting these pathways are advancing through clinical trials.

Conclusions:

  • Targeting intracellular signaling pathways is a key strategy in modern cancer therapy.
  • The development of specific inhibitors shows promise for treating malignancies.
  • Further research into these pathways will likely yield new anticancer drugs.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Intracellular Signaling Cascades01:24

Intracellular Signaling Cascades

Once a ligand binds to a receptor, the signal is transmitted through the membrane and into the cytoplasm. The continuation of a signal in this manner is called signal transduction. Signal transduction only occurs with cell-surface receptors, which cannot interact with most components of the cell, such as DNA. Only internal receptors can interact directly with DNA in the nucleus to initiate protein synthesis. When a ligand binds to its receptor, conformational changes occur that affect the...